why choose us

First received: August 08, 2022

Clinical Trial: Mepolizumab Pharmacokinetics Among Patients With Severe Asthma

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Asthma

Study Type: INTERVENTIONAL


Official Title: Mepolizumab Pharmacokinetics Among Patients With Severe Asthma: Protocol for a Case Control Study Comparing Clinical Responders Versus Non Responders

Brief Summary: Asthma is a chronic disease characterized by inflammation and obstruction of the airways.Identification of the mechanisms of action of corticosteroids has made it possible to define the type 2 inflammation present in nearly 80% of patients with asthma.Monoclonal antibodies (MAb) in severe asthma target type-2 inflammation.Mepolizumab is a humanized IgG1 (immunoglobulin gamma-1) kappa subclass monoclonal antibody directed specifically against interleukin 5 (IL-5).It acts specifically on eosinophil homeostasis, with…

Read more